Tugce Ulasli
YOU?
Author Swipe
Body Mass Index as an Independent Prognostic Factor in Second-Line Nivolumab Therapy for Metastatic Clear Cell Renal Cell Carcinoma Open
Objective: Metastatic renal cell carcinoma (RCC) remains a therapeutic challenge despite significant advances with immune checkpoint inhibitors (ICIs). Nivolumab has demonstrated durable responses in pretreated metastatic clear cell RCC; h…
Sleep Quality and Its Determinants Among Patients with Metastatic Cancer Treated with Immune Checkpoint Inhibitors: A Two-Center Cross-Sectional Study Open
Background and Objectives: Sleep disturbance (SD) is common among cancer patients and may be influenced by immune-related mechanisms during immune checkpoint inhibitor (ICI) therapy. This study evaluated the prevalence and predictors of SD…
Prevalence and Characteristics of Sexual Dysfunction in Patients Treated with Immune Checkpoint Inhibitors Open
Background and Objectives: Sexual dysfunction (SD) is common in cancer but remains poorly characterized among patients receiving immune checkpoint inhibitors (ICIs). This study aimed to determine the prevalence and predictors of SD in ICI-…
Impact of Adipokine Expression on Tumor Characteristics and Survival Outcomes in Patients with Renal Cell Carcinoma Open
Background and Objectives: To investigate the clinical significance of adipokines’ [leptin, leptin receptor (leptin-R), adiponectin, and resistin] expression on the characteristics and survival outcomes of patients with renal cell carcinom…
Early Changes in Volumetric Body Composition Parameters Predict Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy Open
Background/Objectives: The precise role of volumetric body composition (VBC) parameters, visceral adipose tissue index (VATI), subcutaneous adipose tissue index (SATI), and skeletal muscle index (SMI) on the survival of metastatic renal ce…